|NASDAQ: ACHV||Healthcare / Biotechnology / USA|
|4.70||+0.3200||+7.31%||Vol 30.11K||1Y Perf -39.84%|
|Mar 22nd, 2023 15:37 DELAYED|
|0.50 11.42%||- -|
|Target Price||26.80||Analyst Rating||Strong Buy 1.00|
|Potential %||470.21||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★★ — -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||44.08||Earnings Rating||Neutral|
|Market Cap||84.27M||Earnings Date||11th May 2023|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||11th May 2023|
|Estimated EPS Next Report||-0.65|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||108.35K|
|Avg. Monthly Volume||88.40K|
|Avg. Quarterly Volume||103.36K|
Achieve Life Sciences Inc. (NASDAQ: ACHV) stock closed at 4.38 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 119.86K shares and market capitalization of 84.27M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 14 people. Achieve Life Sciences Inc. CEO is John Bencich.
The one-year performance of Achieve Life Sciences Inc. stock is -39.84%, while year-to-date (YTD) performance is 78.78%. ACHV stock has a five-year performance of -98.35%. Its 52-week range is between 2 and 8.125, which gives ACHV stock a 52-week price range ratio of 44.08%
Achieve Life Sciences Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 44.74, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -137.30%, a ROC of -148.59% and a ROE of -251.44%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Achieve Life Sciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.65 for the next earnings report. Achieve Life Sciences Inc.’s next earnings report date is 11th May 2023.
The consensus rating of Wall Street analysts for Achieve Life Sciences Inc. is Strong Buy (1), with a target price of $26.8, which is +470.21% compared to the current price. The earnings rating for Achieve Life Sciences Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Achieve Life Sciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Achieve Life Sciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 21.96, ATR14 : 0.35, CCI20 : -77.61, Chaikin Money Flow : -0.15, MACD : -0.13, Money Flow Index : 34.12, ROC : -14.45, RSI : 41.85, STOCH (14,3) : 16.39, STOCH RSI : 0.53, UO : 37.62, Williams %R : -83.61), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Achieve Life Sciences Inc. in the last 12-months were: Anthony Clarke (Option Excercise at a value of $0), Cindy Jacobs (Option Excercise at a value of $0), Jerry Wan (Option Excercise at a value of $0), John Bencich (Buy at a value of $0), John Bencich (Option Excercise at a value of $0), Richard Alistair Balfour Stewart (Option Excercise at a value of $0)
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline.
CEO: John Bencich
Telephone: +1 425 686-1500
Address: 520 Pike Street, Seattle 98101, WA, US
Number of employees: 14
Sat, 18 Mar 2023 13:25 GMT Achieve Life Sciences (ACHV) Gets a Buy from Maxim Group- TipRanks. All rights reserved.
Fri, 17 Mar 2023 12:30 GMT Analysts Are Bullish on These Healthcare Stocks: Achieve Life Sciences (ACHV), Liquidia Technologies (LQDA)- TipRanks. All rights reserved.
Thu, 09 Mar 2023 19:45 GMT Achieve Life Sciences (ACHV) Receives a Buy from Maxim Group- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.